Geode Capital Management’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-12,604
| Closed | -$271K | – | 4718 |
|
|
2024
Q1 | $271K | Hold |
12,604
| – | – | ﹤0.01% | 3835 |
|
|
2023
Q4 | $46.1K | Hold |
12,604
| – | – | ﹤0.01% | 4369 |
|
|
2023
Q3 | $48.8K | Buy |
+12,604
| New | +$49.2K | ﹤0.01% | 4423 |
|
|
2023
Q2 | – | Sell |
-9,154
| Closed | -$27.3K | – | 4835 |
|
|
2023
Q1 | $27.3K | Sell |
9,154
-70
| -0.8% | -$258 | ﹤0.01% | 4646 |
|
|
2022
Q4 | $46K | Buy |
9,224
+1,469
| +19% | +$5.62K | ﹤0.01% | 4615 |
|
|
2022
Q3 | $50K | Hold |
7,755
| – | – | ﹤0.01% | 4768 |
|
|
2022
Q2 | $56K | Sell |
7,755
-3,591
| -32% | -$32.7K | ﹤0.01% | 4752 |
|
|
2022
Q1 | $167K | Sell |
11,346
-46
| -0.4% | -$1.17K | ﹤0.01% | 4464 |
|
|
2021
Q4 | $546K | Buy |
11,392
+99
| +0.9% | +$10.4K | ﹤0.01% | 4002 |
|
|
2021
Q3 | $1.65M | Sell |
11,293
-1,459
| -11% | -$189K | ﹤0.01% | 3445 |
|
|
2021
Q2 | $1.47M | Buy |
12,752
+1,696
| +15% | +$189K | ﹤0.01% | 3407 |
|
|
2021
Q1 | $1.06M | Buy |
+11,056
| New | +$1.44M | ﹤0.01% | 3525 |
|
Geode Capital Management's LABP Position: Q2 2024 in Review
Geode Capital Management sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2024, closing a stake of 12,604 shares — an estimated $271K sold.
Geode Capital Management first reported a position in LABP in Q1 2021 and held it in 12 quarters. The position peaked at $1.65M in Q3 2021. 0 funds tracked by Wall St. Rank hold LABP as of Q2 2024.
- Geode Capital Management reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Geode Capital Management sold 12,604 Landos Biopharma, Inc. Common Stock shares in Q2 2024, an estimated $271K.
- Geode Capital Management first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
- Geode Capital Management's Landos Biopharma, Inc. Common Stock position peaked at $1.65M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2024.
Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.